MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Eli Lilly and Co.

Fechado

SetorSaúde

819.54 2.1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

796.13

Máximo

819.54

Indicadores-chave

By Trading Economics

Rendimento

7.8B

8.8B

Vendas

2.1B

14B

P/E

Médio do Setor

70.41

63.778

EPS

5.32

Rendimento de Dividendos

0.73

Margem de lucro

65.172

Funcionários

47,000

EBITDA

1.2B

6.1B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+27.58% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.73%

2.39%

Próximos Ganhos

1 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-43B

742B

Abertura anterior

817.44

Fecho anterior

819.54

Sentimento de Notícias

By Acuity

40%

60%

146 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Eli Lilly and Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

1 de abr. de 2025, 23:15 UTC

Grandes Movimentos do Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2 de abr. de 2025, 16:53 UTC

Principais Notícias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

1 de abr. de 2025, 22:31 UTC

Principais Notícias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 de abr. de 2025, 21:47 UTC

Principais Notícias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

14 de mar. de 2025, 09:30 UTC

Principais Notícias

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

28 de fev. de 2025, 12:00 UTC

Principais Notícias

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 de fev. de 2025, 15:14 UTC

Principais Notícias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- Update

26 de fev. de 2025, 14:30 UTC

Principais Notícias

Eli Lilly Plans to Spend $27 Billion on New U.S. Plants -- WSJ

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

7 de fev. de 2025, 10:30 UTC

Principais Notícias

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 de fev. de 2025, 16:16 UTC

Principais Notícias
Ganhos

The Obesity Market Is Growing Just Fine. But Investors Want to Know What's Next -- Heard on the Street -- WSJ

6 de fev. de 2025, 14:56 UTC

Ganhos

Eli Lilly's Disappointing Quarter Was Already Baked In -- Barrons.com

6 de fev. de 2025, 14:32 UTC

Conversa de Mercado
Ganhos

Lilly's Weight-Loss Drug Bonanza Continues -- Market Talk

6 de fev. de 2025, 13:18 UTC

Principais Notícias
Ganhos

Eli Lilly Stock Rises After Earnings Beat Forecasts -- WSJ

6 de fev. de 2025, 12:24 UTC

Ganhos

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance -- Barrons.com

6 de fev. de 2025, 12:01 UTC

Ganhos

Eli Lilly Stock Rises After Earnings Beat -- Barrons.com

6 de fev. de 2025, 11:49 UTC

Ganhos

Eli Lilly Sees Producing at Least 1.6 Times Amount of Salable Incretin Doses in 1st Half of 2025 Vs 1st Half of 2024 >LLY

6 de fev. de 2025, 11:48 UTC

Ganhos

Eli Lilly 4Q U.S. Zepbound Revenue $1.91B >LLY

6 de fev. de 2025, 11:47 UTC

Ganhos

Eli Lilly 4Q Worldwide Mounjaro Revenue Rose 60% to $3.53B >LLY

6 de fev. de 2025, 11:46 UTC

Ganhos

Eli Lilly 4Q Gross Margin 82.2% >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q Trulicity Rev $1.25B >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly Sees FY Adj EPS $22.50-Adj EPS $24.00 >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q Humalog Rev $619.9M >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly Sees FY Rev $58B-$61B >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q Net $4.41B >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q EPS $4.88 >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly Sees FY EPS $22.05-EPS $23.55 >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q Jardiance Rev $1.2B >LLY

6 de fev. de 2025, 11:45 UTC

Ganhos

Eli Lilly 4Q Rev $13.53B >LLY

Comparação entre Pares

Variação de preço

Eli Lilly and Co. Previsão

Preço-alvo

By TipRanks

27.58% parte superior

Previsão para 12 meses

Média 1,043.87 USD  27.58%

Máximo 1,190 USD

Mínimo 900 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Eli Lilly and Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

18

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

797 / 825.32Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

146 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.